Skip to main content

Genecis Bioindustries

MaterialsToronto, CanadaFounded 2017· One of 976 Materials companies tracked by AMPulse

Produces PHA bioplastics from organic food waste via bacterial fermentation, targeting applications including 3D printing filaments, packaging, and biomedical products.

CEO / Founder
Luna Yu
Team Size
11-50
Stage
Growth Stage
Total Funding
$20M
Latest Round
Series A
Key Investors
Khosla Ventures; BDC Capital; Amazon Climate Pledge Fund; AME Cloud Ventures; Gullspang Re:food; IT Farm; Heinz Group; Emerald

Technology & Products

Key Products

Genecis produces PHA bioplastics from organic food waste via bacterial fermentation. These bioplastics are home-compostable and biodegradable, targeting applications such as 3D printing filaments, packaging, and biomedical products.

Technological Advantage

CLAIMED: Patented fermentation process for efficient PHA production from waste streams; VERIFIED: Collaboration with Helian Polymers for 3D printing filament development and $6M NGen funding for scale-up; DEFENSIBLE: Proprietary microbial strains and process IP.

Differentiation

Value Proposition

Offers home-compostable, biodegradable PHA materials that match petroleum-based plastic performance at competitive cost, enabling circular economy solutions and reducing environmental impact.

How They Differentiate

Focuses on food waste as feedstock for PHA production, targeting 3D printing filaments and high-value applications, with partnerships like Helian Polymers for resin formulations, unlike competitors that may use other waste streams or target different markets.

Market & Competition

Target Customers

B2B manufacturers in packaging, textiles, automotive, medical equipment, and additive manufacturing seeking sustainable plastic alternatives.

Industry Verticals

Additive Manufacturing; Packaging; Medical; Textiles; Automotive

Competitors

RWDC Industries; Greenfib; Biome Bioplastics

Growth & Milestones

Growth Metrics

Raised over $20M in total funding; team size around 30-49 employees; sold out for next two years due to high demand for PHAs.

Major Milestones

Founded in 2017; Accepted to Y Combinator Winter 2020; Raised $10M in Series A funding in 2022; Secured $6M project from NGen Canada in 2021; Partnership with Helian Polymers for 3D printing filaments

Notable Customers

StormFisher; Lambton College

https://www.genecis.co

Recent coverage of Genecis Bioindustries

Why this company matters

Genecis Bioindustries occupies a specific niche in the bioplastics market: converting organic food waste into polyhydroxyalkanoate (PHA) using engineered microbes and fermentation. Its process claims to cost up to 40% less than comparable PHA production technologies, addressing the cost barrier that has limited adoption of biodegradable alternatives to petroleum-based plastics. The company targets additive manufacturing, packaging, and biomedical applications, positioning PHA as a drop-in material for filament extrusion.

The core technology is a proprietary fermentation platform that feeds organic waste to engineered bacterial strains, which accumulate PHA within their cells. The resulting bioplastic is home-compostable and biodegradable, with mechanical properties that Genecis says match conventional plastics. A partnership with Helian Polymers focuses on developing PHA-based resin formulations for 3D printing filaments, while a $6 million project from NGen Canada supports scale-up of the production process.

Genecis serves B2B manufacturers in packaging, textiles, automotive, medical equipment, and additive manufacturing. Named customers include StormFisher and Lambton College. The company has raised over $20 million from investors including Khosla Ventures, BDC Capital, and the Amazon Climate Pledge Fund, and reports being sold out for the next two years due to demand. Its microbial strains and process IP form the primary defensible moat, though competition from RWDC Industries and Biome Bioplastics in the broader PHA space remains a risk.